CM
MRNA icon

Crestline Management’s Moderna MRNA Stock Holding History

Crestline Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,139
Closed -$796K – 401
2024
Q4 		$796K Buy
+19,139
New +$915K 0.03% 456

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crestline Management's MRNA Position: Q1 2025 in Review

Crestline Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 19,139 shares — an estimated $796K sold.

Crestline Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $796K in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Crestline Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 19,139 Moderna shares in Q1 2025, an estimated $796K.
  • Crestline Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
  • Crestline Management's Moderna position peaked at $796K in Q4 2024.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.